Karyopharm Therapeutics Inc. (KPTI) stock
KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
$0.04−0.01 (-20.00%)
Close on Nov 9, 2026Market cap $1.16KP/E –Yield –
Karyopharm Therapeutics cash
Cash and short-term investments held at the end of each period.
Karyopharm Therapeutics's cash was $65.10M at Jun 30, 2026. For fiscal 2025 it was $63.70M, down 41.6% from the year before. Over ten years it grew -9.7% a year on average. The highest annual figure on record is $328.92M in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.70M | -41.6% |
| FY2024 | Dec 31, 2024 | $109.05M | -43.0% |
| FY2023 | Dec 31, 2023 | $191.44M | -31.5% |
| FY2022 | Dec 31, 2022 | $279.66M | +18.7% |
| FY2021 | Dec 31, 2021 | $235.60M | -6.7% |
| FY2020 | Dec 31, 2020 | $252.44M | -4.3% |
| FY2019 | Dec 31, 2019 | $263.79M | -19.8% |
| FY2018 | Dec 31, 2018 | $328.92M | +123.8% |
| FY2017 | Dec 31, 2017 | $146.96M | +13.0% |
| FY2016 | Dec 31, 2016 | $130.03M | -26.2% |
| FY2015 | Dec 31, 2015 | $176.12M | -14.4% |
| FY2014 | Dec 31, 2014 | $205.72M | +31.9% |
| FY2013 | Dec 31, 2013 | $155.97M | +39791.0% |
| FY2012 | Dec 31, 2012 | $391.00K | -94.0% |
| FY2011 | Dec 31, 2011 | $6.51M | +89.0% |
| FY2010 | Dec 31, 2010 | $3.45M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $65.10M | +25.9% |
| Q1 FY2026 | Mar 31, 2026 | $90.90M | +30.0% |
| Q4 FY2025 | Dec 31, 2025 | $63.70M | -41.6% |
| Q3 FY2025 | Sep 30, 2025 | $45.90M | -65.6% |
| Q2 FY2025 | Jun 30, 2025 | $51.70M | -66.0% |
| Q1 FY2025 | Mar 31, 2025 | $69.90M | -53.0% |
| Q4 FY2024 | Dec 31, 2024 | $109.05M | -43.0% |
| Q3 FY2024 | Sep 30, 2024 | $133.50M | -35.9% |
| Q2 FY2024 | Jun 30, 2024 | $152.12M | -35.7% |
| Q1 FY2024 | Mar 31, 2024 | $148.58M | -42.9% |
| Q4 FY2023 | Dec 31, 2023 | $191.44M | -31.5% |
| Q3 FY2023 | Sep 30, 2023 | $208.32M | +40.4% |
| Q2 FY2023 | Jun 30, 2023 | $236.77M | +38.6% |
| Q1 FY2023 | Mar 31, 2023 | $260.38M | +26.8% |
| Q4 FY2022 | Dec 31, 2022 | $279.66M | +18.7% |
| Q3 FY2022 | Sep 30, 2022 | $148.38M | -27.3% |
| Q2 FY2022 | Jun 30, 2022 | $170.85M | -27.6% |
| Q1 FY2022 | Mar 31, 2022 | $205.31M | -8.5% |
| Q4 FY2021 | Dec 31, 2021 | $235.60M | -6.7% |
| Q3 FY2021 | Sep 30, 2021 | $204.21M | -22.4% |
| Q2 FY2021 | Jun 30, 2021 | $235.89M | -20.5% |
| Q1 FY2021 | Mar 31, 2021 | $224.37M | -36.3% |
| Q4 FY2020 | Dec 31, 2020 | $252.44M | -4.3% |
| Q3 FY2020 | Sep 30, 2020 | $263.04M | -1.7% |
| Q2 FY2020 | Jun 30, 2020 | $296.72M | +36.6% |
| Q1 FY2020 | Mar 31, 2020 | $352.13M | +33.2% |
| Q4 FY2019 | Dec 31, 2019 | $263.79M | -19.8% |
| Q3 FY2019 | Sep 30, 2019 | $267.53M | +29.4% |
| Q2 FY2019 | Jun 30, 2019 | $217.16M | -9.9% |
| Q1 FY2019 | Mar 31, 2019 | $264.42M | +102.0% |
| Q4 FY2018 | Dec 31, 2018 | $328.92M | +123.8% |
| Q3 FY2018 | Sep 30, 2018 | $206.77M | +73.2% |
| Q2 FY2018 | Jun 30, 2018 | $241.12M | +68.1% |
| Q1 FY2018 | Mar 31, 2018 | $130.92M | +18.6% |
| Q4 FY2017 | Dec 31, 2017 | $146.96M | +13.0% |
| Q3 FY2017 | Sep 30, 2017 | $119.41M | -5.8% |
| Q2 FY2017 | Jun 30, 2017 | $143.45M | – |
| Q1 FY2017 | Mar 31, 2017 | $110.36M | – |
| Q4 FY2016 | Dec 31, 2016 | $130.03M | – |
| Q3 FY2016 | Sep 30, 2016 | $126.81M | – |
See a number that looks wrong?